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ABSTRACT
Objectives: This study aims to investigate the antitrypanosomal inhibitors of Eucalyptus tereticornis for sleeping sickness through molecular docking 
and studies on Absorption distribution metabolism excursion and toxicology (ADMET).
Methods: In silico molecular docking in ArgusLab software and ADMET analysis in AdmetSAR software was performed for the antitrypanosomal 
inhibitors of E. tereticornis for sleeping sickness.
Results: Interactions were studied for the ten proteins responsible for sleeping sickness with the 50 antitrypanosomal inhibitors of E. tereticornis. 
Docking was performed to see the interaction and the best binding energy of compounds with the proteins involved in sleeping sickness. The docking 
scores were highest for betulonic acid with −15.66 kcal/mol followed by euglobal with −12.24 kcal/mol, B-pinene with −10.313 kcal/mol, A-pinene 
with −10.3418 kcal/mol, and the least docking score for P-cymene with −10.6045 kcal/mol. Docking results showed that only betulonic acid and 
euglobal showed that hydrogen bond interaction was as b-pinene, a-pinene, and p-cymene yielded no hydrogen bond interactions so we will be taking 
the former docking results for further studies. The best docking result was shown by betulonic acid with trypanothione reductase giving binding 
energy of −15.66 kcal/mol with hydrogen bond interaction of 2.9, so this result was taken for further analysis.
Conclusion: The results of the compound extracted from E. tereticornis will become physiological relevant only when (i) the pure compounds of this 
plant is available in large quantities; (ii) the Eucalyptus is biochemically stabilized to avoid degradation and enhance absorption in the gastrointestinal 
tract; and (iii) special delivery methods for this drug to reach the areas of treatment. In this work, the efficacy of E. tereticornis to act against 
trypanosomal protein was initiated and thus further research in this process would help us to take full advantage of the remedial effects of the 
compounds extracted from this plant.
Keywords: Antitrypanosomal Inhibitors, Eucalyptus tereticornis, Sleeping sickness, Molecular Docking, ADMET studies.
INTRODUCTION
Human trypanosomiasis, also known as “sleeping sickness,” is caused 
by microscopic parasites of the species Trypanosoma brucei. At 
present, about 10,000 new cases each year are reported to the World 
Health Organization occurred in India in 2007 and re-emerging these 
days; however, it is believed that many cases go undiagnosed and 
unreported. Sleeping sickness is curable with medication but is fatal if 
left untreated [1]. A report on a case of a 37-day-old infant from Uttar 
Pradesh who was presented with fever, lethargy, and convulsions, and 
who had a history of painful insect bite the day before admission [2]. 
In some cases, a pregnant woman can pass the infection to her fetus. 
In theory, the transmission of infection can also be by the transfusion 
of blood or sexual contact, but such cases were rarely documented [3]. 
The course of untreated infection rarely lasts longer than 6–7 years 
and more often kills in about 3 years [4]. The widely used criteria 
for defining the second stage in disease are the observation of 
trypanosomes in CSF or a white blood cell count of six or higher. Other 
indications of the second-stage disease include elevated protein and 
an increase in nonspecific immunoglobulin M in CSF [5]. Medicinal 
plants have served as raw materials for natural product isolation 
and screening. Cetraria islandica is a well-known medicinal plant 
commonly referred to as Iceland moss [6]. Mosses have yielded very 
interesting bioactive compounds in the past. Previous studies have 
yielded from C. islandica, usnic acid and isousnic acid, protolichesteric 
acid, myelochroic acid, lichesterinic acid, praesorediosic acid, phaseolin 
acid, and dihydropertusaric acid, also the naphthazarin, hybocarpone, 
naphthoquinones, anthraquinones, and dibenzofurans. The present 
study demonstrates in vitro antitrypanosomal activity of four isolated 
phytoconstituents from lichen C. islandica and supporting evidence with 
the help of docking studies [7]. Antimicrobial activity was studied on 
the basis of the phytochemical analysis of methanolic extracts from the 
bark and leaf of Eucalyptus tereticornis [8].
The goal of the current study was to identify the protein targets 
that the medicinal plants target selectivity for phytochemical 
classes. In doing so, we have theoretically identified the strongly 
interacting plant chemicals and their biomolecular targets. These 
results should lead to further research to verify the efficacy of 
phytochemical agents [8]. In silico screening of small molecules 
has been at the forefront of drug discovery in recent years. There 
are various drug targets in T. brucei. These include trypanothione 
reductase (TR), rhodesain, triosephosphate isomerase (TIM), and 
farnesyl diphosphate synthase, in line with the fact that target-based 
drug discovery efforts remain a front runner in lead identification 
[9,10]. The clinical significance of the young febrile infant was 
malaria, bacterial sepsis, or viral fever. The clinical diagnosis 
of trypanosomiasis was surprising and incidental because this 
parasitic infection in humans is very rare in India. The characteristic 
morphology and the polymerase chain reaction made the diagnosis 
unequivocal. However, a causal association between the parasite 
and the febrile illness is difficult to establish [11]. The patient was 
treated with suramin, a drug used for the treatment of human African 
trypanosomiasis. The authors hypothesized that the patient was 
infected by a wound in the index finger while delivering an infected 
cattle or a bite by the flies of Tabanidstriatus to transmit infection in 
animals. Subsequently, a serologic study was conducted in the same 
village, and it illustrated that the sera of 81 of 1806 people (4.5%) 
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were seropositive for Trypanosoma evansi infection by the card 
agglutination test but none had parasitemia on peripheral blood [11].
METHODS
Bioinformatics is vital to significantly improve the position and function 
of molecules in binding and simulation. In bioinformatics, the process 
of computer-aided drug design (CADD) exists as a specialized discipline 
to use the computational [12] methods to simulate the interactions 
between a drug and a receptor. CADD methods are heavily dependent on 
bioinformatics tools, applications, and databases. The small molecules 
used in this study have been taken from literature survey; they have 
been selected on the criteria that these ligands have not been used prior 
used as antitrypanosomal studies. The structures of the ligand were 
downloaded directly from PubChem.
Retrieval of the target protein
The 3D structures of the target trypanosomal proteins were downloaded 
from the Protein data bank database (PDB) in.pdb format.
Protein preparation
Protein-ligand docking studies [13] were carried out based on the 
crystal structures of T. brucei adenosine kinase, TbAK (PDB 2xtb and 
PDB 3otx), T. brucei pteridine reductase 1 (TbPTR1), TbPTR1 (PDB 
3jq7), T. brucei dihydrofolate reductase (TbDHFR), TbDHFR (PDB 3rg9 
and PDB 3qfx), T. brucei trypanothione reductase, T. brucei cathepsin B, T. 
brucei heat shock protein 90 (TbHSP90), TbHSP90 (PDB 3omu and PDB 
3opd), T. brucei sterol 14α-demethylase, T. brucei nucleoside hydrolase 
(TbNH), TbNH (PDB 3fz0), T. brucei TIM (TbTIM), and TbTIM (PDB 1iih, 
T. brucei nucleoside 2-deoxyribosyltransferase, and T. brucei ornithine 
decarboxylase, TbODCPDB 1njj). The solvent molecules and the 
cocrystallized ligands were removed from the crystal structure. To be 
used as a receptor for docking, protein structures should be processed. 
Some of the typical operations include (i) addition of hydrogen atoms, 
(ii) elimination of water molecules that are not involved in ligand 
binding, and (iii) making binding groups. This was done in ArgusLab.
Protein-ligand interaction using ArgusLab
The compounds isolated from the plants were docked against the 
proteins using ArgusLab, to find the reasonable binding geometries and 
explore the protein-ligand interactions. Docking of the protein-ligand 
complex was mainly targeted to the predicted active site only. The 
selected residues of the receptor were defined to be a part of the binding 
site. All the compounds in the dataset were docked into the active site 
of the protein following the same procedure. After docking, the docked 
protein (protein-ligand complex) was analyzed to investigate the type 
of interactions. The poses of docking were saved for each compound 
and ranked according to their function. The pose having the highest 
dock score was selected for further analysis [14] (QSAR studies).
RESULTS
This study was conducted to understand the interactions between 
the proteins and the ligand to discover their binding affinity. This 
docking study was executed using ArgusLab. The 3D structure of the 
trypanosomal protein was downloaded from PDB and used as a target 
for docking. The results are as follows.
Protein’s binding site prediction
CASTp was used for predicting the binding site of the protein. The active 
site of protein comprises of amino acid for 3OTX, 3QFX, 3JQ7, 3FZO, 
2XTB, 1NJJ, 3RG9, and 1IIH is listed in Tables 1-8.
In Table 1, the position of amino acids in the active sites of the protein 
with PDB id 3OTX was analyzed by CASTp server.
In Table 2, the position of amino acids in the active sites of the protein 
with PDB id 3QFX was analyzed by CASTp server.
In Table 3, the position of amino acids in the active sites of the protein 
with PDB id 3JQ7 was analyzed by CASTp server.
In Table 4, the position of amino acids in the active sites of the protein 
with PDB id 3FZO was analyzed by CASTp server.
In Table 5, the position of amino acids in the active sites of the protein 
with PDB id 2XTB was analyzed by CASTp server.
Table 1: Active sites of the protein with PDB id 3OTX
S. No. Amino acid Active sites
1 Cystine 12, 123, 239
2 Arginine 7, 34, 58, 70, 94, 132, 156, 223, 245, 265, 
316, 332 
3 Asparagine 13, 56, 67, 195, 222, 231, 295
4 Leucine 15, 16, 39, 134, 138, 286
5 Aspergin 17, 92, 238, 266, 287, 289, 293, 299
6 Serine 19, 64, 197, 269 
7 Alanine 20, 37, 78, 102, 111, 136, 153, 198, 157, 
221, 297, 300, 326
8 Histidine 21, 105, 114, 224, 323
9 Glucine 33, 101, 104, 106, 131, 160, 225, 279, 268, 
241, 228, 328, 339
10 Glycine 35, 62, 63, 81, 107, 129, 298, 296
11 Threonine 36, 85, 172, 264, 270, 280, 325
12 Isoleucine 38, 90, 108, 127, 267, 292, 330
13 Proline 55, 61, 199, 282, 284, 338
14 Valine 57, 60, 68, 71, 98, 109, 283, 240, 125, 278, 
291, 329
15 Tyrosine 59, 79, 95, 165
16 Glutamine 73, 77, 203, 285, 288, 327
17 Trypsin 74
18 Lysins 80, 82, 97, 100, 130, 227, 340
19 Methionine 110, 294, 302
20 Phenylalanine 169, 200, 301
Table 2: Active sites of the protein with PDB id 3QFX
S. No. Amino acid Active sites
1 Arginine 59, 84, 95, 100, 107, 183
2 Leucine 90, 97, 105
3 Aspergin 43, 45, 54, 88, 120
4 Serine 89, 98, 106, 108, 192, 216
5 Alanine 34, 226
6 Histidine 182
7 Glycine 42, 44, 45, 83, 136, 161, 162, 163
8 Threonine 46, 86, 164, 184
9 Isoleucine 41, 47, 51, 118, 160, 165
10 Proline 48, 52, 91, 92,119
11 Valine 32, 33, 195
12 Glutamine 50, 234
13 Trypsin 57, 166
14 Lysins 85, 93, 123, 235
15 Methionine 55, 82
16 Phenylalanine 58, 94, 233
Table 3: Active sites of the protein with PDB Id 3JQ7
S. No. Amino acid Active sites
1 Arginine 89, 98, 106, 108, 192, 216
2 Leucine 90, 97, 105, 137, 168
3 Aspergin 46, 86, 164, 184
4 Serine 43, 45, 54, 88, 120
5 Alanine 34, 226
6 Histidine 52, 60, 101
7 Glycine 42, 44, 45, 83, 136, 161, 162, 163
8 Threonine 46, 86, 164, 184
9 Isoleucine 41, 47, 51, 118, 160, 165
10 Glutamine 50, 234
11 Trypsin 30, 168
12 Lysins 85, 93, 123, 235
13 Methionine 55, 90, 100, 105
14 Phenylalanine 55, 98, 133
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In Table 6, the position of amino acids in the active sites of the protein 
with PDB id 1NJJ was analyzed by CASTp server.
In Table 7, the position of amino acids in the active sites of the protein 
with PDB id 3RG9 was analyzed by CASTp server.
In Table 8, the position of amino acids in the active sites of the protein 
with PDB id 1IIH was analyzed by CASTp server.
Docking of proteins with plant compounds
In this study, the interactions between the ligands and various 
trypanosomal proteins were explored to check their binding affinity; 
docking study was performed using ArgusLab. The interaction between 
the protein and ligand was analyzed on the basis of binding energy and 
the results are compiled in Tables 9-17.
In Table 9, alpha-pinene has the minimum binding energy with pterine 
reductase.
In Table 10, beta-pinene has the minimum binding energy with 
adenosine monophosphate.
Table 4: Active sites of the protein with PDB id 3FZO
S. No. Amino acid Active sites
1 Serine 20, 56, 88
2 Alanine 34, 56, 123, 226
3 Histidine 136, 161, 162, 163
4 Glycine 42, 44, 45, 83
5 Threonine 46, 86, 164, 184
6 Isoleucine 28, 51, 118, 160, 165
7 Glutamine 52, 60, 10150, 234
8 Trypsin 30, 123, 235
9 Lysins 85, 93, 168
10 Methionine 155, 290, 305
11 Phenylalanine 133
Table 5: Active sites of the protein with PDB id 2XTB
S. No. Amino acid Active sites
1 Cystine 25, 33, 140
2 Arginine 57, 60, 68, 71, 98, 109, 283, 240
3 Asparagine 125, 278, 291, 329
4 Alanine 19, 64, 197, 269
5 Histidine 21, 105, 114, 224, 323
6 Glucine 33, 101, 104, 106, 131, 160, 225, 279, 
268, 241, 228, 328, 339
7 Glycine 35, 62, 63, 81, 107, 129, 298, 296
8 Threonine 36, 85, 172, 264, 270, 280, 325
9 Isoleucine 38, 90, 108, 330125, 278, 291, 329
10 Proline 55, 61, 199, 282, 284, 338127, 267, 292
11 Valine 57, 60, 68, 71, 98, 109, 283, 240
12 Tyrosine 59, 79, 95, 165
13 Glutamine 73, 77, 203, 82, 97, 100, 130, 227
14 Trypsin 301
15 Lysins 80, 285, 288, 327340
16 Methionine 200, 74
17 Phenylalanine 169, 110, 294, 302
Table 6: Active sites of the protein with PDB id 1NJJ
S. No. Amino acid Active sites
1 Arginine 33, 35, 106, 108, 192, 216, 289
2 Leucine 105, 137, 168, 190, 197, 206
3 Aspergin 46, 86, 164, 184
4 Serine 43, 45, 54, 88, 120
5 Alanine 34, 226
6 Histidine 52, 60, 101
7 Glycine 42, 44, 45, 83, 136, 161, 162, 163
8 Threonine 46, 86, 164, 184
9 Isoleucine 50, 41, 47, 51
10 Glutamine 234
11 Trypsin 30, 168
12 Lysins 55, 98, 133
13 Methionine 55, 90, 100, 105
14 Phenylalanine 85, 93, 123, 235
Table 7: Active sites of the protein with PDB id 3RG9
S. No. Amino acid Active sites
1 Cystine 20, 37, 78, 102, 111, 136, 153, 198, 
157, 221, 297, 300, 326
2 Arginine 223, 245, 265, 316, 332
3 Asparagine 13, 56, 67, 195, 222, 231, 295
4 Leucine 7, 34, 58 70, 94, 132, 156
5 Aspergin 17, 92, 238, 266, 287, 289, 293, 299
6 Serine 15, 16, 39, 134, 138
7 Alanine 28619, 64, 197, 269, 12, 123, 239
8 Histidine 21, 105, 114, 224, 323
9 Glucine 33, 101, 104, 106, 131, 160, 225, 279, 
268, 241, 228, 328, 339
10 Glycine 35, 62, 63, 81, 107, 129, 298, 296
11 Threonine 36, 85, 172, 264, 270, 280, 325
12 Isoleucine 38, 90, 108, 127, 267, 292, 330
13 Proline 55, 61, 199, 282, 284, 338
14 Valine 57, 60, 68, 71, 98, 109, 283
15 Tyrosine 59, 79, 95, 165, 240, 125, 278, 291, 329
16 Glutamine 73, 77, 203, 285, 288, 327
17 Trypsin 294, 302
18 Lysins 80, 82, 97, 100, 130, 227, 340
19 Methionine 111, 265
20 Phenylalanine 169, 200, 301
Table 8: Active sites of the protein with PDB id 1IIH
S. No. Amino acid Active sites
1 Cystine 25, 33, 140
2 Asparagine 125, 278, 291, 329
3 Arginine 57, 60, 68, 71, 98, 109, 283
4 Alanine 19, 64, 197, 269
5 Histidine 21, 105, 114, 224, 323
6 Glucine 160, 225, 279, 268, 241, 228, 328, 339
7 Glycine 35, 62, 63, 81, 107, 129, 298, 296
8 Threonine 36, 85, 172, 264, 270, 280, 325
9 Isoleucine 33, 101, 104, 106, 131
10 Proline 33, 81, 27, 267, 292
11 Valine 57, 60, 68, 71, 98, 109, 283, 240
12 Tyrosine 59, 79, 95, 165
13 Glutamine 73, 77, 203, 82, 97, 100, 130, 227
14 Trypsin 11, 33, 62
15 Lysins 80, 285, 288, 32, 73, 40
Table 9: Binding of ligands with the pterine reductase
S. No. Protein Ligand Binding enery
1 Pterine reductase Betulonic acid −7.698 kcal/mol
2 Pterine reductase Euglobal −8.24 kcal/mol
3 Pterine reductase Beta pinene −8.313 kcal/mol
4 Pterine reductase Alpha-pinene −10.18 kcal/mol
5 Pterine reductase P-Cymene −8.6045 kcal/mol
Table 10: Binding of ligands with adenosine monophosphate
S. No. Protein Ligand Binding energy
1 Adenosine monophosphate Betulonic acid −9.544 kcal/mol
2 Adenosine monophosphate Euglobal −9.042 kcal/mol
3 Adenosine monophosphate Beta pinene −10.31 kcal/mol
4 Adenosine monophosphate Alpha pinene −8.844 kcal/mol
5 Adenosine monophosphate P-Cymene −8.386 kcal/mol
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In Table 11, P-Cymene has the minimum binding energy with ornithine 
decarboxylase.
In Table 12, alpha-pinene has the minimum binding energy with 
dihydrofolate reductase.
In Table 13, Euglobal has the minimum binding energy with 
dihydrofolate reductase.
In Table 14, betulonic acid has the minimum binding energy with TR.
In Table 15, alpha-pinene has the minimum binding energy with HSP90.
In Table 16, P-Cymene has the minimum binding energy with adenosine 
kinase.
In Table 17, alpha-pinene has the minimum binding energy with 
triosephosphate isomerase.
In Table 18, betulonic acid has the minimum binding energy with 
tyrosine kinase.
Five compounds were selected from the extract of Eucalyptus 
tereticornis and subjected to interaction studies with the ten proteins 
associated with the sleeping sickness disease. The results of docking 
were compared to see the interaction, and the best binding energy is 
given in Table 19. Among 50 compounds, the best compound (shown in 
Table 19) was taken for further studies in QSAR.
In Table 19, betulonic acid has the minimum binding energy with TR 
(3QFX).
The docking scores were highest for betulonic acid with −15.66 
kcal/mol followed by euglobal with −12.24 kcal/mol, B-pinene 
with −10.313 kcal/mol, A-pinene with −10.3418 kcal/mol, and the least 
docking score for P-cymene with −10.6045 kcal/mol. Docking results 
showed that only betulonic acid and euglobal showed that hydrogen 
bond interaction was as b-pinene, a-pinene, and p-cymene yielded no 
hydrogen bond interactions. The best docking result was shown by 
betulonic acid with TR with a binding energy of −15.66 kcal/mol with a 
hydrogen bond interaction of 2.9 angstroms, and this result was taken for 
further analysis in QSAR.
DISCUSSION
In this study, the molecular docking was applied to discover the 
binding [15] mechanism and to correlate its docking score with 
the activity of plant-derived compounds. The TR was subjected to 
molecular docking study with all the five E. tereticornis compounds 
that can act as antitrypanosomiasis drugs (either directly or 
indirectly). The studies by applying the docking technique yielded 
Table 11: Binding of ligands with ornithine decarboxylase
S. No. Protein Ligand Binding energy
1 Ornithine decarboxylase Betulonic acid −8.386 kcal/mol
2 Ornithine decarboxylase Euglobal −7.24 kcal/mol
3 Ornithine decarboxylase Beta-pinene −9.313 kcal/mol
4 Ornithine decarboxylase Alpha-pinene −10.18 kcal/mol
5 Ornithine decarboxylase P-Cymene −10.31 kcal/mol
Table 12: Binding of ligands with dihydrofolate reductase
S. No. Protein Ligand Binding energy
1 Dihydrofolate reductase Betulonic acid −8.313 kcal/mol
2 Dihydrofolate reductase Euglobal −9.313 kcal/mol
3 Dihydrofolate reductase Beta-pinene −8.6045 kcal/mol
4 Dihydrofolate reductase Alpha-pinene −10.41 kcal/mol
5 Dihydrofolate reductase P-Cymene −10.15 kcal/mol
Table 13: Binding of ligands with dihydroorotate dehydrogenase
S. No. Protein Ligand Binding energy
1 Dihydroorotate 
dehydrogenase













Table 14: Binding of ligands with TR
S. No. Protein Ligand Binding energy
1 TR Betulonic acid −15.66 kcal/mol
2 TR Euglobal −9.24 kcal/mol
3 TR Beta-pinene −9.10 kcal/mol
4 TR Alpha-pinene −9.121 kcal/mol
5 TR P-Cymene −9.01 kcal/mol
TR: Trypanothione reductase
Table 15: Binding of ligands with HSP90
S. No. Protein Ligand Binding energy
1 HSP90 Betulonic acid −6.325 kcal/mol
2 HSP90 Euglobal −6.589 kcal/mol
3 HSP90 Beta-pinene −7.546 kcal/mol
4 HSP90 Alpha-pinene −9.122 kcal/mol
5 HSP90 P-Cymene −8.045 kcal/mol
Table 16: Binding of ligands with adenosine kinase
S. No. Protein Ligand Binding energy
1 Adenosine kinase Betulonic acid −7.66 kcal/mol
2 Adenosine kinase Euglobal −12.24 kcal/mol
3 Adenosine kinase Beta-pinene −10.313 kcal/mol
4 Adenosine kinase Alpha-pinene −10.3418 kcal/mol
5 Adenosine kinase P-Cymene −10.6045 kcal/mol
Table 17: Binding of ligands with triosephosphate isomerase
S. No. Protein Ligand Binding energy
1 Triosephosphate 
isomerase






Beta pinene −9.114 kcal/mol
4 Triosephosphate 
isomerase




Table 18: Binding of ligands with tyrosine kinase
S. No. Protein Ligand Binding energy
1 Tyrosine kinase Betulonic acid −10.12 kcal/mol
2 Tyrosine kinase Euglobal −9.982 kcal/mol
3 Tyrosine kinase Beta pinene −9.642 kcal/mol
4 Tyrosine kinase Alpha pinene −10.3418 kcal/mol
5 Tyrosine kinase P-Cymene −9.954 Kcal/mol
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crucial information concerning the orientation of the inhibitors in the 
binding pocket of the target protein. Several potential inhibitors have 
been identified. The results of our present study suggested that it can 
be used for the design and development of novel compounds having 
better inhibitory activity against several types of trypanosomiasis. 
These potential drug candidates can be further be validated in wet 
lab studies for its proper function. In other words, the results of the 
present study can be concluded in the following points. Betulonic 
acid was better ligands of choice that inhibits TR antitrypanosomal 
protein than other ligands showing the best affinity to bind with the 
protein and showed outstanding score and energy when compared 
to all other compounds. By applying QSAR studies to the best-scored 
compounds, it also stands for both properties (drug likeness and 
orally bioavailability).
CONCLUSION
Human trypanosomiasis or sleeping sickness currently is a common 
disease among the rural regions though found rare in the city sides 
causing deaths in humans as well as livestock. Although continuing 
to decline in the city sides, yet incidence rates remain level in rural 
regions following an increase in India since 2007. Trends in human 
trypanosomiasis related death trends due to livestock and causative 
agents over the past several decades. In this field of structure-based drug 
designing, there is a growing interest in the human trypanosomiasis 
protein study for the screening of putative leaf compounds. This 
approach involves the structure-based study of trypanosoma proteins 
and the antitrypanosomal properties of the selected plant compounds 
based on the literature available. The active sites of the trypanosoma 
proteins were found out and the molecular docking of the plant 
compounds was performed. The five compounds were docked, from 
based on the binding energy and the number of hydrogen bonds. 
Among them betulonic acid, a compound in E. tereticornis is found to 
have the best binding affinity and strong hydrogen bond interaction 
with trypanosoma protein. Euglobal, B-pinene, A-pinene, and P-cymene 
also gave good scores.
The results of the compound extracted from E. tereticornis will become 
physiological relevant only when (i) the pure compounds of this plant 
are available in large quantities; (ii) the Eucalyptus is biochemically 
stabilized to avoid degradation and enhance absorption in the 
gastrointestinal tract; and (iii) special delivery methods for this drug to 
reach the areas of treatment. In this work, the efficacy of E. tereticornis 
to act against trypanosomal protein was initiated and thus further 
research in this process would help us to take full advantage of the 
remedial effects of the compounds extracted from this plant. Solving 
these issues in the future would help the in vitro and in vivo studies 
to enhance the possibility of using Eucalyptus in clinical practice. The 
below mentioned wet-lab studies were possible that can be carried 
out in future can be listed as below: (i) The synergistic effect of TR can 
be tested with other compounds; (ii) to test how far these are useful 
in combinatory chemotherapies; (iii) its role in targeting multiple 
arms of the immune system machinery; (iv) identification and effect 
of structurally modified E. tereticornis compounds as trypanosomal 
inhibitors; and (v) real-life challenges and possibility in bringing up 
these inhibitors as orally available drugs or even as energy drinks.
Table 19: Selected compounds with the least binding energy
S. No Protein Ligand Binding energy (kcal/mol) No. of h-bond interactions (angstroms)
1 Trypanothione reductase (3QFX) Betulonic acid −15.66 1 (2.90000)
2 Adenosine kinase (3OTX) Euglobal −12.24 3 (2.715618, 2.947590, and 2.454139)
3 Adenosine kinase (3OTX) B-pinene −10.31 0
4 Adenosine kinase (3OTX) A-pinene −10.3418 0
5 Adenosine kinase (3OTX) P-cymene −10.6045 0
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